Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Pulmonary Blastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Pancreatic Neoplasms 1Pain, Intractable 1Neuroblastoma 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Melanoma, Cutaneous Malignant 1Melanoma 1Lymphoma 1Li-Fraumeni Syndrome 1Leukemia, Plasma Cell 1Leukemia 1Legius syndrome 1Hematologic Neoplasms 1Gliosarcoma 1

Interventions

ribociclib 1exemestane 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Drug Therapy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × Anatomic Stage II Breast Cancer AJCC v8 × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡